Discover
CLLS
Cellectis S.A.
2.94
1 x 3.00
1 x 3.03
bid
ask
-
0.06
2.00%
1 @ 04:00 PM
2.88 -0.06 (2.04%)
| Ytd | -39.26% | |
| 1y | 89.68% |
2.90
day range
2.98
1.54
52 week range
5.48
| Open | 2.96 | Prev Close | 3.00 | Low | 2.90 | High | 2.98 | Mkt Cap | 295.80M |
| Vol | 23.44K | Avg Vol | 38.55K | EPS | -0.67 | P/E | N/A | Forward P/E | -2.07 |
| Beta | 3.20 | Short Ratio | 1.41 | Inst. Own | 16.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 3.48 | 200-d Avg | 3.82 | 1yr Est | 6.67 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-04 | 2024-09 | -0.2 | -0.23 | -0.03 | -15.00% |
| 2024-08-06 | 2024-06 | -0.33 | -0.28 | 0.05 | 15.15% |
| 2024-05-28 | 2024-03 | 0 | -0.15 | N/A | N/A |
| 2024-04-29 | 2023-12 | 0 | -0.64 | N/A | N/A |
| 2023-11-06 | 2023-09 | -0.36 | -0.31 | 0.05 | 13.89% |
| 2023-08-03 | 2023-06 | -0.38 | -0.14 | 0.24 | 63.16% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-05 | Barclays | Upgrade | Overweight | Overweight |
| 2024-06-12 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-05-31 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2023-11-01 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2023-08-08 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2023-08-07 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
Profile
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Long Focus Capital Management, LLC | 4.62M | 7.26M | 6.40% |
| 2024-09-29 | Capital International Investors | 1.85M | 2.91M | 2.56% |
| 2024-09-29 | UBS Asset Management Americas Inc | 1.44M | 2.26M | 1.99% |
| 2024-09-29 | Baillie Gifford and Company | 693.94K | 1.09M | 0.96% |
| 2024-09-29 | Principal Financial Group, Inc. | 411.80K | 647.31K | 0.57% |
| 2024-09-29 | Macquarie Group Limited | 226.88K | 356.62K | 0.31% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Smallcap World Fund | 1.85M | 2.91M | 2.56% |
| 2024-07-30 | Principal Small Cap Fund | 284.40K | 447.05K | 0.39% |
| 2024-09-29 | Delaware Group Equity Fds IV-Delaware Healthcare Fund | 226.88K | 356.62K | 0.31% |
| 2024-07-30 | Vanguard Whitehall Funds-International Explorer Fund | 122.03K | 191.82K | 0.17% |
| 2024-09-29 | JNL Series Trust-JNL/Multi Manager Int'l Small Cap Fund | 116.75K | 183.53K | 0.16% |
| 2024-08-30 | Trust for Professional Managers-ActivePassive International Equity ETF | 58.31K | 91.66K | 0.08% |